Vertex Historical Balance Sheet

VRTX Stock

USD 501.72 15.02 2.91%

Trend analysis of Vertex Pharmaceuticals balance sheet accounts such as Total Assets of 23.9 B, Short Long Term Debt Total of 848.8 M, Other Current Liabilities of 3.1 B or Total Current Liabilities of 3.7 B provides information on Vertex Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Vertex Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Vertex Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Oil Shock

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Vertex Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Vertex Pharmaceuticals is a good buy for the upcoming year.

Vertex Pharmaceuticals Inventory

775.74 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.

About Vertex Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Vertex Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Vertex Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Vertex Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Vertex currently owns. An asset can also be divided into two categories, current and non-current.

Vertex Pharmaceuticals Balance Sheet Chart

At this time, Vertex Pharmaceuticals' Cash And Short Term Investments are fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 23.9 B in 2024, despite the fact that Net Debt is likely to grow to (9.1 B).

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity Capital Surpluse

Add Fundamental

Total Assets

Total assets refers to the total amount of Vertex Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vertex Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Vertex Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Vertex Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Most accounts from Vertex Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Vertex Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.At this time, Vertex Pharmaceuticals' Cash And Short Term Investments are fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 23.9 B in 2024, despite the fact that Net Debt is likely to grow to (9.1 B).

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	556.7M	561M	808.4M	848.8M
Total Assets	13.4B	18.2B	22.7B	23.9B

Short Long Term Debt Total Total Assets

Vertex Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Property Plant And Equipment Gross	Net Receivables	Common Stock Total Equity	Common Stock	Other Assets	Long Term Debt
Total Assets		0.29	0.96	0.98	1.0	0.88	-0.98	0.94	0.99	0.99	0.89	0.99	0.21	0.58	0.45	0.59	0.99	1.0	-0.06	0.98	0.94	0.99	0.36	0.37	0.86	0.04
Short Long Term Debt Total	0.29		0.26	0.31	0.26	0.52	-0.17	0.05	0.23	0.33	0.11	0.26	0.62	0.69	0.26	0.65	0.42	0.27	0.41	0.38	0.34	0.24	0.71	0.71	0.15	0.6
Other Current Liab	0.96	0.26		0.99	0.96	0.81	-0.92	0.94	0.93	0.96	0.82	0.94	0.11	0.47	0.54	0.48	0.94	0.95	-0.16	0.95	0.89	0.94	0.28	0.29	0.77	0.04
Total Current Liabilities	0.98	0.31	0.99		0.98	0.84	-0.94	0.94	0.95	0.98	0.84	0.96	0.17	0.51	0.57	0.54	0.97	0.97	-0.09	0.97	0.91	0.97	0.33	0.34	0.82	0.03
Total Stockholder Equity	1.0	0.26	0.96	0.98		0.88	-0.98	0.95	0.99	0.99	0.89	0.99	0.18	0.55	0.44	0.57	0.98	1.0	-0.08	0.97	0.94	0.99	0.34	0.35	0.87	0.01
Property Plant And Equipment Net	0.88	0.52	0.81	0.84	0.88		-0.83	0.72	0.86	0.88	0.76	0.88	0.46	0.79	0.2	0.8	0.91	0.88	-0.07	0.86	0.91	0.86	0.61	0.61	0.75	0.26
Net Debt	-0.98	-0.17	-0.92	-0.94	-0.98	-0.83		-0.94	-1.0	-0.94	-0.96	-0.99	-0.2	-0.55	-0.38	-0.54	-0.96	-0.99	0.06	-0.95	-0.94	-0.99	-0.33	-0.34	-0.84	0.0
Retained Earnings	0.94	0.05	0.94	0.94	0.95	0.72	-0.94		0.94	0.93	0.84	0.93	-0.1	0.34	0.47	0.29	0.89	0.94	-0.12	0.93	0.88	0.93	0.06	0.07	0.79	-0.14
Cash	0.99	0.23	0.93	0.95	0.99	0.86	-1.0	0.94		0.96	0.95	1.0	0.21	0.58	0.39	0.57	0.97	1.0	-0.05	0.96	0.95	0.99	0.35	0.36	0.84	0.02
Non Current Assets Total	0.99	0.33	0.96	0.98	0.99	0.88	-0.94	0.93	0.96		0.83	0.96	0.19	0.54	0.49	0.59	0.98	0.97	-0.06	0.96	0.91	0.97	0.36	0.37	0.88	0.04
Non Currrent Assets Other	0.89	0.11	0.82	0.84	0.89	0.76	-0.96	0.84	0.95	0.83		0.94	0.27	0.58	0.25	0.54	0.88	0.92	-0.04	0.86	0.9	0.94	0.35	0.36	0.75	0.03
Cash And Short Term Investments	0.99	0.26	0.94	0.96	0.99	0.88	-0.99	0.93	1.0	0.96	0.94		0.23	0.6	0.4	0.59	0.98	1.0	-0.07	0.97	0.95	0.99	0.37	0.38	0.85	0.04
Common Stock Shares Outstanding	0.21	0.62	0.11	0.17	0.18	0.46	-0.2	-0.1	0.21	0.19	0.27	0.23		0.65	-0.01	0.82	0.3	0.22	0.18	0.2	0.27	0.23	0.97	0.97	0.23	0.6
Non Current Liabilities Total	0.58	0.69	0.47	0.51	0.55	0.79	-0.55	0.34	0.58	0.54	0.58	0.6	0.65		-0.11	0.79	0.67	0.59	0.1	0.61	0.66	0.57	0.72	0.73	0.39	0.53
Other Current Assets	0.45	0.26	0.54	0.57	0.44	0.2	-0.38	0.47	0.39	0.49	0.25	0.4	-0.01	-0.11		0.13	0.46	0.43	0.27	0.47	0.29	0.43	0.1	0.1	0.33	-0.2
Other Stockholder Equity	0.59	0.65	0.48	0.54	0.57	0.8	-0.54	0.29	0.57	0.59	0.54	0.59	0.82	0.79	0.13		0.66	0.58	0.07	0.55	0.58	0.59	0.87	0.88	0.59	0.41
Total Liab	0.99	0.42	0.94	0.97	0.98	0.91	-0.96	0.89	0.97	0.98	0.88	0.98	0.3	0.67	0.46	0.66		0.99	0.01	0.98	0.94	0.98	0.46	0.47	0.83	0.12
Total Current Assets	1.0	0.27	0.95	0.97	1.0	0.88	-0.99	0.94	1.0	0.97	0.92	1.0	0.22	0.59	0.43	0.58	0.99		-0.06	0.98	0.95	0.99	0.36	0.37	0.85	0.03
Short Term Debt	-0.06	0.41	-0.16	-0.09	-0.08	-0.07	0.06	-0.12	-0.05	-0.06	-0.04	-0.07	0.18	0.1	0.27	0.07	0.01	-0.06		-0.02	-0.04	-0.04	0.18	0.18	-0.18	-0.15
Accounts Payable	0.98	0.38	0.95	0.97	0.97	0.86	-0.95	0.93	0.96	0.96	0.86	0.97	0.2	0.61	0.47	0.55	0.98	0.98	-0.02		0.94	0.96	0.37	0.38	0.81	0.1
Property Plant And Equipment Gross	0.94	0.34	0.89	0.91	0.94	0.91	-0.94	0.88	0.95	0.91	0.9	0.95	0.27	0.66	0.29	0.58	0.94	0.95	-0.04	0.94		0.95	0.4	0.41	0.78	0.11
Net Receivables	0.99	0.24	0.94	0.97	0.99	0.86	-0.99	0.93	0.99	0.97	0.94	0.99	0.23	0.57	0.43	0.59	0.98	0.99	-0.04	0.96	0.95		0.36	0.37	0.86	0.02
Common Stock Total Equity	0.36	0.71	0.28	0.33	0.34	0.61	-0.33	0.06	0.35	0.36	0.35	0.37	0.97	0.72	0.1	0.87	0.46	0.36	0.18	0.37	0.4	0.36		1.0	0.34	0.61
Common Stock	0.37	0.71	0.29	0.34	0.35	0.61	-0.34	0.07	0.36	0.37	0.36	0.38	0.97	0.73	0.1	0.88	0.47	0.37	0.18	0.38	0.41	0.37	1.0		0.35	0.6
Other Assets	0.86	0.15	0.77	0.82	0.87	0.75	-0.84	0.79	0.84	0.88	0.75	0.85	0.23	0.39	0.33	0.59	0.83	0.85	-0.18	0.81	0.78	0.86	0.34	0.35		0.01
Long Term Debt	0.04	0.6	0.04	0.03	0.01	0.26	0.0	-0.14	0.02	0.04	0.03	0.04	0.6	0.53	-0.2	0.41	0.12	0.03	-0.15	0.1	0.11	0.02	0.61	0.6	0.01

Click cells to compare fundamentals

Vertex Pharmaceuticals Account Relationship Matchups

Vertex Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.3B	11.8B	13.4B	18.2B	22.7B	23.9B
Short Long Term Debt Total	577.4M	581.5M	556.7M	561M	808.4M	848.8M
Other Current Liab	1.0B	1.2B	1.5B	1.9B	2.9B	3.1B
Total Current Liabilities	1.2B	1.6B	1.9B	2.4B	3.5B	3.7B
Total Stockholder Equity	6.1B	8.7B	10.1B	13.9B	17.6B	18.5B
Property Plant And Equipment Net	745.1M	958.5M	1.1B	1.1B	1.5B	1.5B
Net Debt	(2.5B)	(5.4B)	(6.2B)	(9.9B)	(9.6B)	(9.1B)
Retained Earnings	(1.9B)	858.7M	3.2B	6.5B	10.1B	10.6B
Cash	3.1B	6.0B	6.8B	10.5B	10.4B	10.9B
Non Current Assets Total	3.7B	3.9B	4.4B	5.5B	8.6B	9.0B
Non Currrent Assets Other	326.9M	662.5M	901.1M	1.3B	796.7M	836.5M
Cash And Short Term Investments	3.8B	6.7B	7.5B	10.8B	11.2B	11.8B
Common Stock Shares Outstanding	260.7M	263.4M	259.9M	259.1M	260.5M	153.1M
Liabilities And Stockholders Equity	8.3B	11.8B	13.4B	18.2B	22.7B	23.9B
Non Current Liabilities Total	1.0B	1.5B	1.5B	1.8B	1.6B	1.7B
Other Current Assets	213.5M	308.4M	187.2M	74.4M	620.5M	651.5M
Other Stockholder Equity	7.9B	7.9B	6.9B	7.4B	7.4B	7.8B
Total Liab	2.2B	3.1B	3.3B	4.2B	5.1B	5.4B
Total Current Assets	4.6B	7.8B	9.0B	12.7B	14.1B	14.9B
Short Term Debt	30.3M	42.4M	46.9M	89.4M	83.7M	51.0M
Accounts Payable	87.6M	155.1M	195M	303.9M	364.9M	383.1M
Property Plant And Equipment Gross	745.1M	958.5M	2.3B	2.5B	2.6B	2.8B
Accumulated Other Comprehensive Income	(2.0M)	(68.5M)	15.9M	800K	(14.3M)	(13.6M)
Net Receivables	633.5M	885.4M	1.1B	1.4B	1.6B	1.6B
Common Stock Total Equity	2.6M	2.6M	2.5M	2.6M	3.0M	1.9M
Common Stock	2.6M	2.6M	2.5M	2.6M	3.0M	2.0M
Other Assets	1.2B	587.0M	986.9M	1.4B	1.6B	1.7B
Short Term Investments	699.0M	670.7M	729.9M	274.5M	849.2M	579.6M
Property Plant Equipment	833.3M	958.5M	1.1B	1.5B	1.7B	1.8B
Other Liab	275.5M	923.4M	902.2M	685.8M	788.7M	828.1M
Current Deferred Revenue	62.3M	191.5M	171.7M	159.6M	170.3M	118.8M
Inventory	167.5M	280.8M	353.1M	460.6M	738.8M	775.7M
Net Tangible Assets	4.7B	7.3B	8.7B	12.2B	14.1B	14.8B
Retained Earnings Total Equity	(1.9B)	858.7M	3.2B	6.5B	7.5B	7.9B
Long Term Debt Total	583.9M	581.6M	538.6M	539.0M	619.9M	632.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CRM	Salesforce
CRM	Salesforce
S	SentinelOne

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vertex Historical Balance Sheet

Vertex Pharmaceuticals Inventory

775.74 Million

About Vertex Balance Sheet Analysis

Vertex Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Vertex Pharmaceuticals balance sheet Correlations

Vertex Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Vertex Pharmaceuticals balance sheet Accounts

Also Currently Popular

Additional Tools for Vertex Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 1.0	Net Debt
Net Receivables	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Net Debt	- 0.98	Total Stockholder Equity
Net Debt	- 0.98	Total Assets